A new federal court is now handling employer complaints about insurance companies and pharmacy benefit managers colluding to charge inflated prices for insulin.

Dozens of school districts across the United States are joining forces to sue various pharmaceutical companies and pharmacy benefit managers (PBMs) over allegations of price-gouging for insulin. The legal action is focused on the skyrocketing cost of insulin, which has led to difficulties in providing affordable medication to students with type 1 diabetes. UnitedHealthcare is among the defendants. The class-action lawsuits allege that the defendants engaged in a conspiracy to artificially inflate prices, resulting in exorbitant costs for patients and school districts. The lawsuits also contend that the defendants profited from the price hikes, while leaving patients and families with limited options. The school districts are seeking compensation for the financial burdens imposed by the alleged price gouging, as well as damages for the harm caused to students, parents, and the overall community. This collective effort aims to hold the pharmaceutical companies and PBMs accountable for their actions and to make insulin more accessible and affordable for those in need.